Fabrication and evaluation of dexmedetomidine hydrochloride microneedles based on 3D printing.
- Author:
Yuanke YANG
1
;
Xiaolu HAN
2
;
Xianfu LI
2
;
Xiaoxuan HONG
2
;
Shanshan YANG
3
;
Chunyan LIU
1
;
Zengming WANG
2
;
Aiping ZHENG
1
Author Information
- Publication Type:Journal Article
- Keywords: 3D printing; dexmedetomidine hydrochloride; dissolving microneedle; transdermal drug delivery
- MeSH: Dexmedetomidine/pharmacokinetics*; Printing, Three-Dimensional; Needles; Drug Delivery Systems/methods*; Administration, Cutaneous; Animals; Microinjections/instrumentation*; Skin Absorption; Skin/metabolism*
- From: Chinese Journal of Biotechnology 2025;41(8):3214-3227
- CountryChina
- Language:Chinese
- Abstract: Compared with conventional transdermal drug delivery systems, dissolving microneedles significantly enhance drug bioavailability by penetrating the stratum corneum barrier and achieving intradermal drug delivery. In order to improve the transdermal bioavailability of dexmedetomidine hydrochloride, in this study, a novel microneedle delivery system was developed for dexmedetomidine hydrochloride based on 3D printing combined with micro-molding. By systematically optimizing the microneedle geometrical parameters, array arrangement, and preparation process parameters, we determined the optimal ratio of drug-carrying matrix as 15% PVP (polyvinyl pyrrolidone) K90. The microneedles exhibited significant drug loading gradients, with mean content of (209.99±27.56) μg/patch, (405.31±30.31) μg/patch, and (621.61±34.43) μg/patch. They showed a regular pyramidal structure under SEM and handheld electron microscopy, and their mechanical strength allowed effective penetration into the stratum corneum. The surface contact angles were all < 90°, indicating excellent hydrophilicity. The microneedles dissolved completely within 10 min after skin insertion, achieving a cumulative release rate of 90% (Higuchi model, r=0.996) during 2 hours of in vitro transdermal permeation. The cytotoxicity test and hemolysis test verified good biocompatibility. Pharmacodynamic evaluation showed that the microneedle group demonstrated pain-relieving effect within 15 min, with the pain threshold at the time point of 60 min being 3 times that in the transdermal cream group. The microneedle system developed in this study not only offers an efficient drug delivery option for patients but also establishes an innovative platform for rapid percutaneous delivery of hydrophilic drugs, demonstrating significant potential in perioperative pain management.
